bpc-157 adverse effects human case report BPC 157 Side Effects: What You Should Know FDA advisers narrowly vote to

In a 2001 study published in Endocrinology , Heffernan and colleagues reported that chronic AOD-9604 administration reduced body weight gain, decreased adipose tissue mass, and increased fat oxidation in obese mice without altering IGF-1 levels or glucose metabolism effects that were abolished in beta3 adrenergic receptor (3-AR) knockout mice, implicating 3-AR signaling as the mechanism of action [1]

The peptide is not FDA-approved for any medical condition and is typically used as a research compound or through compounding pharmacies

Rodriguez-Iturbe B, Johnson RJ

Selecting the right peptide depends on your unique health objectives

Well, I got the deal to do the NBC